Comparative Pharmacology
Head-to-head clinical analysis: ENOVID versus ENOVID E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID versus ENOVID E.
ENOVID vs ENOVID-E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (LH, FSH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases viscosity of cervical mucus and alters endometrial lining to impair implantation.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
Oral, 5 mg daily for 20 days starting on day 5 of menstrual cycle for ovulation inhibition; for endometriosis, 5 mg daily for 15 days increasing to 10 mg daily if breakthrough bleeding occurs.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
None Documented
None Documented
Norethynodrel: 5-12 hours; mestranol: 7-20 hours. Terminal half-life of ethinyl estradiol from mestranol conversion: 10-30 hours. Clinical context: steady-state achieved after 3-5 half-lives (3-5 days).
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Renal (30-50% as metabolites, <5% unchanged) and fecal (40-60% via bile, mostly as glucuronide conjugates).
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive